Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kilitch Drugs (India) Buyback Yield % Related Terms
Kilitch Drugs (India) Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:KILITCH vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a Buyback Yield % of -7.53 as of Jul. 17, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Kilitch Drugs (India) and its competitors. According to the industry distribution chart, Kilitch Drugs (India) ranks #214 out of 291 companies in the Drug Manufacturers industry, placing it in the top 73.5%.
Is Kilitch Drugs (India)'s Buyback Yield % too high?
Kilitch Drugs (India)'s current Buyback Yield % is -7.53. Based on the distribution chart, Kilitch Drugs (India) ranks #214 out of 291 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #214 out of 291 companies for Buyback Yield %. This places Kilitch Drugs (India) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current Buyback Yield % is -7.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.73, compared to a current price of ₹182.75 — trading 19.4% below its estimated fair value. The current Buyback Yield % is -7.53. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Buyback Yield % is -7.53 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹182.75 is trading 19.4% below its estimated GF Value™ of ₹226.73.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
Buyback Yield %: -7.53
GF Value™: ₹226.73 vs. price of ₹182.75 (19.4% below fair value)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score
Get the complete analysis for NSE:KILITCH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
